FDA approves UroGen’s Zusduri to treat recurrent bladder cancer - PharmaTimes Approximately 59,000 LG-IR-NMIBC patients experience recurrent disease every year in the US

#bladdercancer #FDA #mitomycin #NMIBC #UroGenPharma #Zusduri #mitomycinintravesicalsolution #FDAapproved #LGIRNMIBC #LGIRNMIBCpatients #FoodandDrugAdministration #bladdercancerpatients #recurrentLGIRNMIBC #TURBT #bladdercancertreatment #ENVISIONclinicaltrial
pharmatimes.com/news/fda-app...

New insights into decades-old bladder cancer treatment may enhance immunotherapy strategies – BioNews Central Over 30 years after the FDA approved the BCG vaccine as the first cancer immunotherapy for early-stage bladder cancer, researchers are advancing knowledge of its mechanism to potentially enhance immunotherapy effectiveness overall. ...

Over 30 years after the FDA approved the #BCGvaccine as the first #CancerImmunotherapy for early-stage #BladderCancer, researchers are advancing knowledge of its mechanism to potentially enhance #immunotherapy effectiveness overall.
#BladderCancerTreatment